Connect Biopharma Cash Per Share vs. Total Debt
| CNTB Stock | USD 1.00 0.01 1.01% |
Cash Per Share | First Reported 2010-12-31 | Previous Quarter 2.15470163 | Current Value 2.22 | Quarterly Volatility 1.23823061 |
For Connect Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Connect Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Connect Biopharma Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Connect Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Connect Biopharma Holdings over time as well as its relative position and ranking within its peers.
Connect |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Revenue Per Share 0.438 | Return On Assets (0.12) | Return On Equity (0.18) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Connect Biopharma Total Debt vs. Cash Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Connect Biopharma's current stock value. Our valuation model uses many indicators to compare Connect Biopharma value to that of its competitors to determine the firm's financial worth. Connect Biopharma Holdings is number one stock in cash per share category among its peers. It is rated below average in total debt category among its peers making up about 19,991 of Total Debt per Cash Per Share. At present, Connect Biopharma's Cash Per Share is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Connect Biopharma's earnings, one of the primary drivers of an investment's value.Connect Total Debt vs. Cash Per Share
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Connect Biopharma |
| = | 23.26 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Connect Biopharma |
| = | 465 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Connect Total Debt vs Competition
Connect Biopharma Holdings is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 146.13 Million. Connect Biopharma adds roughly 465,000 in total debt claiming only tiny portion of equities under Health Care industry.
Connect Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Connect Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Connect Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Connect Biopharma's change in net profit over the period of time. It can combine multiple indicators of Connect Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 11.9 M | 12.4 M | |
| Net Loss | -1.2 B | -1.1 B | |
| Net Interest Income | 2.7 M | 2.8 M | |
| Interest Income | 2.7 M | 3.5 M | |
| Operating Income | -62.1 M | -65.2 M | |
| Net Loss | -59.5 M | -62.5 M | |
| Income Before Tax | -59.4 M | -62.4 M | |
| Total Other Income Expense Net | 2.7 M | 2.8 M | |
| Net Loss | -59.4 M | -62.4 M | |
| Income Tax Expense | 120 K | 126 K | |
| Change To Netincome | 847.5 M | 889.9 M | |
| Net Loss | (1.08) | (1.13) | |
| Income Quality | 0.81 | 0.46 | |
| Net Income Per E B T | 1.00 | 0.80 |
Connect Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Connect Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Connect Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Connect Biopharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Connect Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
Use Investing Themes to Complement your Connect Biopharma position
In addition to having Connect Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Penny Thematic Idea Now
Penny
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
To fully project Connect Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Connect Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Connect Biopharma's income statement, its balance sheet, and the statement of cash flows.